Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
16 December, 2018 07:27 IST
Strides Shasun receives USFDA approval for Efavirenz tablets
Source: IRIS | 14 Mar, 2018, 09.44AM
Comments  |  Post Comment

Strides Shasun today announced that it's wholly owned subsidiary Strides Pharma Global has received approval for Efavirenz Tablets USP, 600 mg from the United States Food & Drug Administration (US FDA). Efavirenz Tablet is generic version of Sustiva Tablets of Bristol-Myers Squibb Company.

According to IQVIA data, the US market for Efavirenz Tablets USP, 600 mg is approximately USD 115 Million and Strides is only the second generic company to get the approval for the product under the para IV route. The product will be manufactured at the company's Oral dosage facility at Bangalore and will be marketed by Strides Pharma Inc. in the US Market. Strides is launching the product immediately.

The company has 74 cumulative ANDA filings with USFDA of which 44 ANDAs have been approved as of date and 30 are pending approval.

Shares of the company gained Rs 7.55, or 1.12%, to trade at  Rs 683.30.  The total volume of shares traded  was  2,073 at the BSE (9.31 a.m., Wednesday).



Strides Pharma Science Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Related Articles
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer